COLAL-PRED Alizyme

Curr Opin Investig Drugs. 2004 Nov;5(11):1192-7.

Abstract

COLAL-PRED (prednisolone sodium metasulfobenzoate), which is targeted to the colon by COLAL colonic drug delivery technology, is being developed by Alizyme for the potential treatment of inflammatory bowel disease. Alizyme expect to initiate a phase III trial in 2005.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Humans
  • Inflammatory Bowel Diseases / drug therapy*
  • Prednisolone / adverse effects
  • Prednisolone / analogs & derivatives*
  • Prednisolone / metabolism
  • Prednisolone / therapeutic use*
  • Structure-Activity Relationship

Substances

  • prednisolone 21-3-sulfobenzoate
  • Prednisolone